Evaluating criteria for reversing liver fibrosis in patients with NASH

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients diagnosed with non-alcoholic fatty liver disease (NAFLD) who have non-alcoholic steatohepatitis (NASH) and fibrosis stages F2-4 confirmed by liver biopsy. It aims to collect clinical and pathological data to establish a new pathological evaluation system for assessing fibrosis reversal in NASH. Additionally, the study seeks to identify non-invasive indicators for monitoring this reversal process. By analyzing these data, the researchers hope to refine the criteria for evaluating liver fibrosis in affected patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged between 18 and 70 years at the time of liver biopsy;
* Gender is not limited;
* Hepatic perforation suggested that NASH complicated with fibrosis stage F2-4;
* Signed written informed consent.

Exclusion Criteria:

* Combined HCV infection, HIV infection, alcoholic liver disease, autoimmune liver disease, genetic metabolic liver disease Disease, drug-induced liver injury and other chronic liver diseases;
* Women during pregnancy;
* There are the following conditions before liver perforation: HCC or possible HCC (imaging suggests malignant liver occupation); decompensation of cirrhosis (ascites, hepatic encephalopathy, gastrointestinal bleeding, hepatorenal syndrome, etc.); Patients with other malignant tumors; Recipients of liver transplantation;
* Patients considered by the investigator to be unsuitable for this study.

Where it's running

• Beijing Ditan Hospital, Capital Medical University
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Minghui Li
• Email: wuhm2000@sina.com
• Phone: +8613693259096

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Additive Physical Activity for Hypothyroidism in Older Women with Glaucoma and Fatty Liver

  We’re testing whether adding a treadmill-based exercise program to standard thyroid treatment helps improve health in older women who have subclinical hypothyroidism, glaucoma, and fatty liver.

  Recruiting Cairo University · Dokki, Giza Governorate · NCT07599241

• Lowering insulin to reduce liver fat production

  This study will try a short course of diazoxide to lower insulin and see if it reduces the liver's creation of new fat in adults with obesity, insulin resistance, and MASLD.

  Recruiting Phase 1 Columbia University · New York, New York · NCT07403604

• Efimosfermin alfa for adults with liver impairment

  This trial will test a single dose of efimosfermin alfa in adults with cirrhosis-related hepatic impairment from steatotic liver disease, with and without significant alcohol use, to measure drug levels and safety.

  Recruiting at 5 sites Phase 1 GlaxoSmithKline · Rialto, California and 4 other locations · NCT07358546

• Efimosfermin alfa for adults with biopsy-confirmed F2 or F3 MASH

  This trial will test whether efimosfermin alfa can resolve steatohepatitis and improve liver-related outcomes in adults with biopsy-confirmed F2 or F3 MASH.

  Recruiting at 91 sites Phase 3 GlaxoSmithKline · Chandler, Arizona and 90 other locations · NCT07221227

• Efimosfermin alfa injections for adults with F2–F3 MASH

  This study tests whether efimosfermin alfa injections are safe and tolerable for adults (18–75) with known or suspected metabolic dysfunction-associated steatohepatitis (MASH) and F2–F3 fibrosis.

  Recruiting at 66 sites Phase 3 GlaxoSmithKline · Arcadia, California and 65 other locations · NCT07221188

• Mediterranean diet with or without aerobic exercise for women with familial Mediterranean fever and fatty liver

  This trial will test whether adding regular aerobic exercise to a Mediterranean diet helps women with familial Mediterranean fever who have non-alcoholic fatty liver disease.

  Recruiting Cairo University · Dokki, Giza Governorate · NCT07130318

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.